SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NYMXF Alzheimer's treatment!
NYMXF 0.1060.0%Oct 31 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jean-Robert Grenier who wrote (79)3/20/1998 1:03:00 PM
From: Apple Jacks  Read Replies (1) of 132
 
Just to follow-up on Ian's posting as luck would have it there's an article in the The Globe & Mail (a Canadian paper) that is available on-line at:
theglobeandmail.com

I left a message on another thread (Misc. Biotech/Medical)about Nymox in response to a person who is bullish on Nymox. I have cut some of that text into this posting.


1) Everyone should know that this is the debut issue of the Journal of Alzheimer's Disease and the editor of the Journal is none other than a Nymox consultant who has been working for them since May, 1996.

REACH YOUR OWN CONCLUSIONS!

2)If this were a real breakthrough it would have been in Science or Nature.

3)Who's on the BOD doesn't always mean anything. Bre-X had some good Directors.

4)I haven't met one clinician, academic, investor, or biotech analyst who has had anything positive to say about Nymox. Maybe it's just the people that I know!?

5)I have seen a lot of patents that claim a lot but have never materialized. Do you think all the patent reviewers are AD experts? Holding a patent isn't as good an indicator of how good the science is compared to publishing in reputable journals. It really hasn't been peer-reviewed! If in a couple of months time, the scientific community embraces the "revolutionary" work Nymox has done then great! I would be wrong and I wouldn't care because there would now be some even more hope for the millions of AD sufferers.

6) Please remember that they are a few years away from being in Phase II or III, when the compound's efficacy will really be known.

BTW, I am not shorting the stock. There is no financial gain in this for me.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext